A tumor waste chemical can shut off an immune alarm
Original title: Lactate-Induced K370 Lactylation of STING Inhibits STING-TBK1 Signaling and Dampens Anti-Tumor Immunity.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in lab samples and in mice.
The short version
In lab and mouse tests, blocking a tumor waste chemical helped immune treatments work better.
What was studied. Researchers looked at a protein called STING. It acts like an alarm that tells the immune system to attack a tumor. They tested it in lab tumor samples grown from patients and in mice with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
What they found. Tumors make a waste chemical called lactate. The team found that lactate sticks to STING and jams it. The jammed alarm cannot team up with its partner protein, so the immune signal stays weak. When the team used a drug to block lactate, the alarm worked again. In mice, adding that drug made STING treatments work better, alone and with another immune drug.
What this means, and what it doesn't
What it could mean: This points to a possible way to help some immune treatments do their job. It gives researchers a clear idea to test next in the lab and, later, maybe in people.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in lab samples and in mice, not in people. No one has shown that it helps patients live longer or feel better. It is very early science, far from everyday care. It is not a cure and not something you can ask your doctor for now.
Source: PubMed, August 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.